Cargando…

Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients

BACKGROUND: Complement plays a pivotal role in the immune response to infection. Several studies demonstrated complement activation in sepsis, yet little is known of the relationship of complement terminal pathway activation and the clinical characteristics of sepsis patients. Therefore, we investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmad, Fatima M, A Al-Binni, Maysaa’, Bani Hani, Amjad, Abu Abeeleh, Mahmoud, Abu-Humaidan, Anas H A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760944/
https://www.ncbi.nlm.nih.gov/pubmed/35046691
http://dx.doi.org/10.2147/JIR.S344282
_version_ 1784633428261470208
author Ahmad, Fatima M
A Al-Binni, Maysaa’
Bani Hani, Amjad
Abu Abeeleh, Mahmoud
Abu-Humaidan, Anas H A
author_facet Ahmad, Fatima M
A Al-Binni, Maysaa’
Bani Hani, Amjad
Abu Abeeleh, Mahmoud
Abu-Humaidan, Anas H A
author_sort Ahmad, Fatima M
collection PubMed
description BACKGROUND: Complement plays a pivotal role in the immune response to infection. Several studies demonstrated complement activation in sepsis, yet little is known of the relationship of complement terminal pathway activation and the clinical characteristics of sepsis patients. Therefore, we investigated serum C5, soluble C5b-9 (sC5b-9), and soluble CD59 (sCD59) and their relation to organ failure in sepsis patients in the intensive care unit (ICU). METHODS: In this prospective cohort study, all available patients admitted to the adult ICUs between June 2020 and January 2021 were included. Patients were divided into sepsis and non-sepsis groups according to the Sepsis-3 criteria, serum samples from both groups were investigated for the levels of C5, sC5b-9, and sCD59 using commercial sandwich ELISA kits. RESULTS: We analyzed 79 serum samples, 36 were from sepsis patients. We found that sepsis patients had significantly lower C5 (83.6± 28.4 vs 104.4± 32.0 µg/mL, p = 0.004) and higher sCD59 (380.7± 170.5 vs 288.9± 92.5 ng/mL, p = 0.016). sC5b-9, although higher in sepsis patients, did not reach statistical significance (1.5± 0.8 µg/mL vs 1.3± 0.7 µg/mL, p = 0.293). Sepsis patients who died during their ICU stay had significantly higher sCD59 compared to those who survived (437.0 ± 176.7 vs 267.8 ± 79.7 ng/mL, p = 0.003, respectively). Additionally, C5 and sCD59 both correlated to SOFA score in the sepsis group (r(s) = −0.44, P = 0.007 and = 0.43, P = 0.009, respectively), and a similar correlation was not found in the non-sepsis group. DISCUSSION: In sepsis patients, levels of C5 and sCD59, but not sC5b-9, correlated to the severity of organ damage measured by SOFA. A similar correlation was not found in non-sepsis patients. This indicated that organ damage associated with sepsis led to a more pronounced terminal pathway activation than in non-sepsis patients, it also indicated the potential of using C5 and sCD59 to reflect sepsis severity.
format Online
Article
Text
id pubmed-8760944
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-87609442022-01-18 Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients Ahmad, Fatima M A Al-Binni, Maysaa’ Bani Hani, Amjad Abu Abeeleh, Mahmoud Abu-Humaidan, Anas H A J Inflamm Res Original Research BACKGROUND: Complement plays a pivotal role in the immune response to infection. Several studies demonstrated complement activation in sepsis, yet little is known of the relationship of complement terminal pathway activation and the clinical characteristics of sepsis patients. Therefore, we investigated serum C5, soluble C5b-9 (sC5b-9), and soluble CD59 (sCD59) and their relation to organ failure in sepsis patients in the intensive care unit (ICU). METHODS: In this prospective cohort study, all available patients admitted to the adult ICUs between June 2020 and January 2021 were included. Patients were divided into sepsis and non-sepsis groups according to the Sepsis-3 criteria, serum samples from both groups were investigated for the levels of C5, sC5b-9, and sCD59 using commercial sandwich ELISA kits. RESULTS: We analyzed 79 serum samples, 36 were from sepsis patients. We found that sepsis patients had significantly lower C5 (83.6± 28.4 vs 104.4± 32.0 µg/mL, p = 0.004) and higher sCD59 (380.7± 170.5 vs 288.9± 92.5 ng/mL, p = 0.016). sC5b-9, although higher in sepsis patients, did not reach statistical significance (1.5± 0.8 µg/mL vs 1.3± 0.7 µg/mL, p = 0.293). Sepsis patients who died during their ICU stay had significantly higher sCD59 compared to those who survived (437.0 ± 176.7 vs 267.8 ± 79.7 ng/mL, p = 0.003, respectively). Additionally, C5 and sCD59 both correlated to SOFA score in the sepsis group (r(s) = −0.44, P = 0.007 and = 0.43, P = 0.009, respectively), and a similar correlation was not found in the non-sepsis group. DISCUSSION: In sepsis patients, levels of C5 and sCD59, but not sC5b-9, correlated to the severity of organ damage measured by SOFA. A similar correlation was not found in non-sepsis patients. This indicated that organ damage associated with sepsis led to a more pronounced terminal pathway activation than in non-sepsis patients, it also indicated the potential of using C5 and sCD59 to reflect sepsis severity. Dove 2022-01-08 /pmc/articles/PMC8760944/ /pubmed/35046691 http://dx.doi.org/10.2147/JIR.S344282 Text en © 2022 Ahmad et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ahmad, Fatima M
A Al-Binni, Maysaa’
Bani Hani, Amjad
Abu Abeeleh, Mahmoud
Abu-Humaidan, Anas H A
Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
title Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
title_full Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
title_fullStr Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
title_full_unstemmed Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
title_short Complement Terminal Pathway Activation is Associated with Organ Failure in Sepsis Patients
title_sort complement terminal pathway activation is associated with organ failure in sepsis patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760944/
https://www.ncbi.nlm.nih.gov/pubmed/35046691
http://dx.doi.org/10.2147/JIR.S344282
work_keys_str_mv AT ahmadfatimam complementterminalpathwayactivationisassociatedwithorganfailureinsepsispatients
AT aalbinnimaysaa complementterminalpathwayactivationisassociatedwithorganfailureinsepsispatients
AT banihaniamjad complementterminalpathwayactivationisassociatedwithorganfailureinsepsispatients
AT abuabeelehmahmoud complementterminalpathwayactivationisassociatedwithorganfailureinsepsispatients
AT abuhumaidananasha complementterminalpathwayactivationisassociatedwithorganfailureinsepsispatients